Clinical efficacy and safety of biapenem for febrile neutropenia in patients with underlying hematopoietic diseases: a multi-institutional study.
A multi-institutional study was conducted to assess efficacy and safety of biapenem (BIPM), a carbapenem antibiotic, as an initial-stage therapeutic agent for febrile neutropenia (FN) in patients with hematopoietic diseases. A total of 216 patients from 25 medical institutions were enrolled in this study; of these, 204 were included in the safety analysis and 178 in the efficacy analysis. The combined (excellent and good) response rate was 67.9%, and antipyretic effect (subsidence + tendency to subsidence) was achieved within 3 and 5 days of treatment in 67.3 and 75.9% of patients, respectively. Thus, the clinical responses were gratifying. A response rate of 61.7% (37/60) was observed even in high-risk FN patients in whom neutrophil counts prior to and at 72 h after the start of BIPM were ≤100/μl. BIPM is considered to be a highly promising drug, with prompt onset of clinical benefit, as an initial-stage therapeutic agent for the treatment of FN in patients with hematopoietic diseases.
Nakagawa
Yasunori
Y
Department of Oncology and Hematology, Japanese Red Cross Medical Center, Tokyo, Japan. y-nak@white.plala.or.jp
Suzuki
Kenshi
K
Hirose
Takayuki
T
Chou
Takaaki
T
Fujisawa
Shin
S
Kida
Michiko
M
Usuki
Kensuke
K
Ishida
Yoji
Y
Taniguchi
Shuichi
S
Kouzai
Yasuji
Y
Tomoyasu
Shigeru
S
Miyazaki
Koji
K
Higashihara
Masaaki
M
Ando
Kiyoshi
K
Aoki
Sadao
S
Arai
Ayako
A
Akiyama
Nobu
N
Hatake
Kiyohiko
K
Okamoto
Shinichiro
S
Dan
Kazuo
K
Ohyashiki
Kazuma
K
Urabe
Akio
A
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000890:Anti-Infective Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001419:Bacteria / Q000187:drug effects; D005260:Female; D005334:Fever / Q000097:blood / Q000188:drug therapy*; D019337:Hematologic Neoplasms / Q000097:blood / Q000150:complications*; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000150:complications / Q000188:drug therapy*; D009504:Neutrophils; D013845:Thienamycins / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
D000890:Anti-Infective Agents; D013845:Thienamycins; C065257:biapenem